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Introduction: Patients undergoing hematopoietic cell
transplantation (HCT) have an increased risk of Clostridium
difﬁcile infection (CD). Literature reports CD infection in
nearly 20% of transplanted patients. No information about
this infection in HCT patients has been reported in Chile.
Patients and Methods: We performed a retrospective
analysis of 250 patients undergoing HCT at the Catholic
University Hospital in Santiago, Chile, between 2000 and
2013. Statistical analysis of the data was conducted using
SPSS Statistics v21.
Results: Of the 250 transplanted patients studied, 59%
(n¼147) were allo-HCT and 41% (n¼103) were auto-HCT. The
mean age was 39 years old (range, 15-69), with a male
predominance (151 patients; 60%). Main indications for HCT
were acute leukemia (n¼104; 42%), multiple myeloma
(n¼36; 14%) and lymphoma (n¼49; 20%). 93% of patients
received myeloablative (MA) regimens, and all of them
received proton pump inhibitors and prophylactic antibiotics
the previous months of the HCT. Of the 250 patients studied,
192 (77%) had at least one episode of diarrhea that required
study, among them 13% (n¼25) were documented as positive
for CD (toxin assay or PCR test), the mean age of this group
was 36 years old (range, 18-62), with a male predominance
(15 patients, 60%). All of the infected patients had mild to
moderate diseases and there were no deaths attributed to it.
80% (n¼20) of the infected patients underwent allo-HCT and
20% (n¼5) auto-HCT. In the allo-HCT group, 53% had acute
lymphoblastic leukemia, 6% acute myeloid leukemia, 24%
chronic myeloid leukemia and 12% other causes. In the
auto-HCT group, 40% were transplanted due to multiple
myeloma, 20% amyloidosis, 20% germinal cancer and 20%
acute myeloid leukemia. No patient required total central
parenteral nutrition previous to the infection. During the 3
months before HCT, 84% (n¼21) of the infected patients
used antibiotics including cephalosporins, carbapenem,
aminoglicosides and vancomycin. The overall incidence of CD
infection in the ﬁrst week, month and year after transplant,
was 4%, 6% and 10%, respectively, with a median time frame
from transplantation to infection diagnosis of 20 days. In
auto-HCT, 7 days, 30 days and 1 year CD incidence was 2, 3
and 5%, respectively. In allo-HCT, 7 days, 30 days and 1 year
CD incidence was 5, 9 and 14%, respectively. There was no
signiﬁcant statistical difference in overall survival (OS)
between the infected and non-infected patients one year
after the transplant (OS 68% for CD negative vs. 72% for CD
positive, p¼0.61).
Conclusions: In our institution CD infection in patients
undergoing HCT had a similar incidence to other reports.
Most of cases occur before the ﬁrst week after HCT (40% of
the cases), and the remained stable afterwards. We identiﬁed
the type of transplant (allo-HCT 3 times higher risk than
auto-HCT) and disease (ALL 3 times higher risk than AML) as
risk factors for CD infection.361
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hematologic malignancies and hematopoietic cell trans-
plantation (HCT). Optimal nutritional status is associated
with a shorter time of engraftment and less infection rates
during the initial phase. We present our experience in
nutritional assessment pre and post transplantation.
Objective: To evaluate the possible association between
nutritional parameters and outcomes such as overall survival
and speciﬁc complications, in patients who underwent HCT.
Patients and Methods: Retrospective study in patients with
HCT between June 2011 and May 2014 in our center. We
assessed nutritional status before transplantation and then
10 days after it. Nutritional assessment included anthro-
pometry, body mass index (BMI), albumin, prealbumin and
total urinary nitrogen (TUN). Statistical analysis was made
using IBP SSPS v.20.
Results:We studied a total of 50 patients between June 2011
andMay 2014. Media following time: 35months. Median age
was 41 years (18-67), 33 (66%) were male and 17 (33%)
female. Thirty two underwent (64%) allogeneic HCT and 18
(36%) autologous HSCT, with 42 undergoing (84%) myeloa-
blative conditioning and 8 (16%) reduced intensity condi-
tioning. Diagnoses included acute leukemia (26), lymphoma
(7), multiple myeloma (13), and aplastic anemia (3). Thirty
seven patients developed mucositis and 31 required paren-
teral nutrition (PN). Twenty three patients developed
mucositis and required PN (mild: 2, moderate: 20, severe: 1)
Incidence of mucositis between allogeneic and autologous
HCT that required PN was similar (75% vs 72%). Albumin
levels were 4,1mg/dL before and 3,3 mg/dL 10 days after
HSCT (p<0,05). No difference was found between BMI,
dynamometry and TUN before and after HCT. TUN before
HCT was associated with more days of PN (p<0,05). Multi-
variate analysis showed an association between lower
albumin levels after HCT and PN requirement, as well as a
longer length of stay. High TUN and lower albumin levels
after HCT were associated with longer platelet engraftment
time (p<0,05). Longer engrafment time was associated with
longer duration of PN (p<0,05). Nine patients (28%) in the
allogeneic group developed acute gastrointestinal graft
versus host disease (GVHD) that required prolonged PN. No
association was found between BMI, albumin, prealbumin,
TUN or requirement of PN, with the risk of mucositis or
infectious complications. None of the evaluated nutritional
parameters were associated with overall survive (OS).
Conclusion: High catabolism was associated with a longer
length of stay, the requirement of PN and a prolonged
platelet engraftment time. Acute gastrointestinal GVHD was
associated with more requirement and a longer duration of
PN. Nutritional parameters were not associated with any risk
of infection and OS.362
Single Dose Plerixafor and Multi-Day Apheresis: Skip
Dosing Enables Cost Efﬁcient Mobilization for Patients
Close to Achieving Treatment Goals
Jeffrey Schriber 1, Andrew Szetela 1, Aleksandra Schriber 2,
Eileen Simpson 1, Donald Israel 1, Gail Sulski 1, Nicole Thurman 1,
Rochelle Chiffelle 1, Kate Steenstra 1, Denise Gibson 1,
Selma Kendrick 1, Jonathan Abbas 1, Adrienne Briggs 1. 1 BMT,
Cancer Transplant Institute, Scottsdale, AZ; 2 Knox College,
Galesburg, IL
Plerixafor (P) is highly effective at mobilizing peripheral
blood stem cells. Most centers, including our own, have an
algorithm that utilizes P in patients who are predicted to
have poor collections using G CSF alone, based on peripheral
Median Pre
CD34 /uL
Median CD34/ kg
Initial Collection
Median CD34/ kg
Second Collection
Median % of
Initial Collection
Days to ANC
>0.5 x109/L
Days to Plt
>50 x109/L
NHL (n¼7) 2.1 (1.5-6.2) 1.5 (1.27-1.68) 0.68 (0.27-1.96) 41% (21-114) 11 (10-12) 16 (11->28)
MM (n¼3) 3.1 (3.1-5.7) 3.01 (1.85-3.77) 1.51 (1.11-3.01) 60% (40-85) 11 (9-12) 14 (13-14)
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high cost of P and the inability to determine which patients
will collect poorly using clinical parameters alone.
Previous studies have shown that the high cost of P is
justiﬁed based on fewer apheresis days required. However
when patients require 2 or more days of P the costs can
become prohibitive.
To alleviate the need for additional days of P we piloted an
approach where patients who were close to achieving their
target collection goal after the ﬁrst day of P continued their G
CSF, but without an additional dose of P. Minimum accepted
collection goals were 2 x 106 CD34/kg for NHL patients and 4
x 106CD34/kg for MM patients.
From April 2012 through April 2014 170 patients underwent
an autologous transplant. Fifty (29.4%) ultimately required P
to mobilize adequate numbers of cells. Ten patients (7 NHL, 3
MM) were judged close to their preset target collection goal
after their ﬁrst dose of P. These patients were collected the
following day without an additional dose of P.
As shown in Table 1 the median peripheral blood CD34/uL
count prior to collection was 2.1 for NHL and 3.1 for MM. The
median CD34 x 106/kg collected the day following the dose of
P was 1.5 (NHL) and 3.01 (MM). On the second day of
collection without P, the median CD34 x 106collected was
0.68 (NHL) and 1.51 (MM). All patients achieved their target
goals and were able to successfully proceed to trans-
plantation. The median percentage of the original collection
is 40 and 60% respectively for NHL and MM. All patients
engrafted with similar times to patients not requiring P, or
who had a successful collection with a single apheresis.
It appears that in patients who are close to achieving their
target dose, that the strategy of omitting the second dose of P
can successfully allow collection of sufﬁcient cells to permit
autologous transplant with appropriate engraftment times.
In our population 20% of the patients who received P fell into
this category.With a cost of approximately $7000 per patient
dose, the cost savings per 100 patients transplanted would
be approximately $42,000. Such an approach clearly
can minimize the costs associated with stem cell
mobilization and collection without any difference in the
clinical outcome.363
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Ambisome (amphotericin B liposomal complex, L-Amb) is
highly effective for the treatment of invasive fungal
infections (IFI) and may be an important prophylactic drug in
patients undergoing hematopoietic stem cell transplant(HSCT). Several new anti-fungal drugs have become available
over the past few years leading to various prospective studies
aiming to assess the role of prophylaxis and treatment in IFI
in HSCT. But drug related factors such as safety, efﬁcacy,
toxicity proﬁle in the setting of pre-existing organ dysfunc-
tion and potential drug interaction, need to be considered.
Ambisome is a liposomal formulation containing ampho-
tericin B and is comparatively found to cause fewer infu-
sional reactions and achieve superior plasma and tissue
concentrations.
To determine the optimal approach for prophylactic
antifungal therapy, we prospectively analyzed the efﬁcacy
and safety of low dose Ambisome, which is 1mg per kg
body weight on alternate days in nineteen patients who
underwent hematopoietic stem cell transplant at our insti-
tute, for the prophylaxis of IFI. This was a heterogeneous
study group, having varied indications for transplant.
Results: The low dose regimen of 1mg/kg body weight on
alternate days was well tolerated. Four out of nineteen
patients developed manageable hypokalemia. No renal
toxicity or infusional reactions were documented. However,
a test dosewas always administered. Only one patient having
a T replete haploidentical transplant for follicular lymphoma
developed probable IFI requiring anti-fungal therapy.
Conclusion: We conclude that low dose L-Amb may provide
useful protection against invasive fungal infections in
patients undergoing hematopoietic stem cell transplant.364
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Respiratory and skeletal muscle strength and submaximal
exercise capacity and physical activity levels are known to be
reduced in a signiﬁcant percentage of patients prior to
hematopoietic stem cell transplantation (HSCT). However,
determinants of physical activity levels of HSCT recipients
have not been investigated so far. The aim of this study was
to determine the role of physical activity levels in HSCT
recipients.
Patients and Methods: This prospective cross sectional
study included 36 HSCT recipients. Physical activity levels
were assessed using a multisensory armband device and
pulmonary function tests. Functional exercise capacity was
evaluated with 6-minute walking test (6MWT), respiratory
muscle strength (MIP, MEP) with mouth pressure device,
peripheral muscles strength with dynamometer, and
dyspnea with Modiﬁed Medical Research Council
(MMRC) dyspnea scale. Correlations of exercise capacity
parameters were done with the grade of cardiac and
pulmonary toxicity, febrile neutropenia, and transplant
related mortality (TRM).
Results: All HSCT recipients were inactive (<3.0 METs)
according to daily average METs (1.260.18 METs) and
